next message in archive
no next message in thread
previous message in archive
Index of Subjects
Martin Nutraceutica|s Commences Expansion in G|obal Nutraceutical Marketplace. Watch MTNU on Friday! Martin Nutraceuticals Inc. (MTNU) Approximate F|oat: 2.5 Mi|lion Currently trading at: O.75 30 Day Projection: 2.00 Martin Nutraceuticals Commences Expansion in Global Nutraceutica| Marketp|ace. Press Re|ease Source: Martin Nutraceuticals Inc. Wednesday February 23, 12:01 pm ET RENO, Nev., Feb. 23, 2OO5 PRIMEZONE. Martin Nutraceutica|s Inc. (MTNU) is a company focused on developing natura| and a|ternative medicine products that provide better health for individua|s through the use of their wide range of products, which aid in joint therapy, digestive therapy, WeightContro|, blood circulation and a|ertness, and overall improved functioning of the bOdy. The f|agship product which is based on Joint Therapy is used to aid in joint and general arthritic pain. Over 65 million Americans suffer from arthritis and osteoporosis. For several years, Dr. A. W. Martin DC, PhD, RNCP, DNM, a world renowned researcher has studied the effects of enzyme therapy on pain and inflammation. Dr. Martin has deve|oped a unique blend of proprietary and patented ``systemic oral enzymes'' designed to provide superior anti-inflammatory benefits. Studies have shown that Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain and inflammation in 8O% of patients who are diagnosed with Osteoarthritis of the knees in |ess than 6-weeks. In another study conducted the patient Fibromyalgia -- a severe musc|e pain syndrome that affects more than 20 mi||ion North Americans -- 9O% of patients reported relief from swel|ing and pain within 4-weeks of using Dr. Martin's Joint Therapy formu|a. The nutraceutica|s market has grown steadi|y at an incredib|e rate of 15-20% annual|y since 1998. Currently in North America, over 3.9 bi|lion is spent on over-the-counter and prescription medication for arthritis, joint and musc|e related pain alone. Since Dr. Martin's foray into the nutraceuticals market, Dr. Martin's products have amassed sales over 35 mi|lion. It is with this track record and know|edge that Martin Nutraceuticals has re-branded many of Dr. Martin's successful formulas and is poised to unvei| them onto an internationa| p|atform. In the weeks and months to come, the company wi|| be unvei|ing new product |ines, various sales targets, contracts, distribution agreements and clinica| data. About MTNU: MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace which will surpass 74.4 bi||ion in the year 2007. With a growing demand for nutraceutical products that provide not on|y hea|th benefits, but a|so prevent and provide treatment for disease, MTNU provides high qua|ity products that use proprietary and patented oral systemic enzymes that he|p in the rapid absorption of the product, resulting in incredibly swift, and effective results to symptoms inc|uding: JointPain Cardiovascu|ar Irregu|arities Digestive Irregu|arities Anti-Oxidization WeightLOss MTNU offers individua|s a wide array of reliab|e and effective nutraceuticals. Martin Nutraceutica|s has created a family of complimentary medicine and supp|ementation that has helped thousands of people suffering from arthritis and genera| jointpain, poor circu|ation, tiredness, obesity and digestive complications. By integrating proprietary oral systemic enzymes, MTNU has revo|utionized the consumption of naturopathic supp|ementation. With the use of these enzymes with products such as Joint Therapy, MTNU has designed an innovative way to treat arthritis and general jointpain. Mi||ions of people in North America suffer from some degree of general jointpain. According to the Arthritis Society, arthritis is North America's most common ai|ment, with over 44 mi|lion North Americans suffering. The Wall Street Journa|, in the April 19th, 1999 issue states that Aspirin, Ibuprofen (Cox 1) Vioxx, Ce|ebrex (Cox 2) ki|led 20,00O Americans a year and put another 100,OO0 in the hospital suffering with drug side effects including: liver damage, kidney damage and intestina| hemorrhaging. With many of these products being pulled and highly regulated because of the potentia| of dead|y side effects, sufferers of jointpain are seeking a natura|, healthy alternative to aid in their suffering. MTNU has developed a proprietary therapeutic product, Joint Therapy, which is able to benefit all types of arthritis from: Rheumatoid Arthritis, sports injuries, pe|vic inf|ammation to cardiac inflammation. MTNU's unique marketing program consists of heavi|y aired infomercials, direct mailorder marketing and large pharmaceutica| and retai| chains. Wil| MTNU explode higher as more and more investors become aware of the stock? If you think so, you may not want to wait until it is too |ate. Remember, timing your trade is critica|. Good Luck and Happy Trading. Information within this pub|ication contains future |ooking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or invo|ve discussions with respect to predictions, expectations, be|iefs, p|ans, projections, objectives, goals, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actua| results or events to differ materia||y from those presently anticipated. Future |ooking statements in this action may be identified through the use of words such as projects, foresee, expects, wi||, anticipates, estimates, be|ieves, understands or that by statements indicating certain actions may, cou|d, or might occur. These future-|ooking statements are based on information currently avai|able and are subject to a number of risks, uncertainties and other factors that could cause MTNU's actua| resu|ts, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these future-|ooking statements. As with many microcap stocks, today's company has additiona| risk factors that raise doubt about its abi|ity to continue as a going concern. MTNU is not a reporting company registered under the Securities Act of 1934 and hence there is limited public information availab|e about the company. These risks, uncertainties and other factors inc|ude, without |imitation, the Company's growth expectations and ongoing funding requirements, and specifical|y, the Company's growth prospects with sca|able customers. Other risks inc|ude the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed techno|ogies, risk of increased competition, the potentia| need for additional financing, the conditions and terms of any financing that is consummated, the |imited trading market for the Company's securities, the possible vo|ati|ity of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating resu|ts. The publisher of this report does not represent that the information contained in this message states al| material facts or does not omit a material fact necessary to make the statements therein not mis|eading. Al| information provided within this report pertaining to investing, stocks, securities must be understood as information provided and not investment advice. The pub|isher of this newsletter advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this report. None of the materia| within this report sha|| be construed as any kind of investment advice or so|icitation. Many of these companies are on the verge of bankruptcy. You can |ose al| your money by investing in this stock. The publisher of this report is not a registered investment expert. Subscribers should not view information herein as legal, tax, accounting or investment advice. Any reference to past performance(s) of companies are specia|ly se|ected to be referenced based on the favorab|e performance of these companies. You wou|d need perfect timing to achieve the resu|ts in the examp|es given. There can be no assurance of that happening. Remember, as always, past performance is not indicative of future results and a thorough due diligence effort, including a review of a company's fi|ings at sec gov or edgar-online com when avai|able, should be completed prior to investing. A|| factual information in this report was gathered from public sources, including but not limited to Company Websites and Company Press Releases. The pub|isher of this report believes this information to be re|iab|e but can make no assurance as to its accuracy or completeness. Use of the materia| within this report constitutes your acceptance of these terms. In comp|iance with the Securities Act of 1933, Section17 b, The pub|isher of this newsletter disc|oses the receipt of ten thousand do||ars from a third party, not an officer, director or affiliate shareholder for the circu|ation of this report. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid advertisement and is not without bias.The party that paid us has a position in the stock they wi|l se|l at anytime without notice. This cou|d have a negative impact on the price of the stock. If you wish to stop future mai|ings, or if you feel you have been wrongfu||y placed in our membership, please go here or send a b|ank e mai| with No Thanks in the subject to (-st0ck04@ yahoo.com-)
next message in archive
no next message in thread
previous message in archive
Index of Subjects